Literature DB >> 26486735

Multinucleation is an objective feature useful in the diagnosis of pleomorphic lobular carcinoma in situ.

Luis Z Blanco1, Tiffany A Thurow1, Aparna Mahajan1, Barbara Susnik2, Irene Helenowski3, Joan S Chmiel3, Megan E Sullivan4.   

Abstract

OBJECTIVES: Bi- and multinucleated (B/M) cells are present in a variety of tumors. We evaluated lobular carcinoma in situ (classic and pleomorphic types) and ductal carcinoma in situ (DCIS) to determine if this objective morphologic feature aids the differential diagnosis.
METHODS: The number of B/M cells was recorded in pleomorphic lobular carcinoma in situ (PLCIS) (n = 20), classic lobular carcinoma in situ (CLCIS) (n = 26), and DCIS (n = 37).
RESULTS: Binucleated cells were significantly more frequent in PLCIS (100%) vs DCIS (43%; P < .0001) and CLCIS (54%; P = .0004). Multinucleated cells were present in 25% of PLCIS cases and 8% of DCIS cases, and they were absent in CLCIS. The quantity of B/M per high-power field (hpf) was less in DCIS (mean, 1.1) and CLCIS (mean, 2.5) compared with PLCIS (mean, 5.8). Thirty-five percent of PLCIS cases had more than five B/M per hpf.
CONCLUSIONS: Binucleated cells are significantly more frequent in PLCIS vs CLCIS and DCIS. Multinucleated cells were never identified in CLCIS. PLCIS should be considered as a diagnosis when B/M is noted. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Binucleation; Ductal carcinoma in situ; Lobular carcinoma in situ; Multinucleation; Pleomorphic

Mesh:

Substances:

Year:  2015        PMID: 26486735     DOI: 10.1309/AJCPZHZ2TUE2UYNV

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  1 in total

1.  A Soft Microenvironment Protects from Failure of Midbody Abscission and Multinucleation Downstream of the EMT-Promoting Transcription Factor Snail.

Authors:  Allison K Simi; Alişya A Anlaş; Melody Stallings-Mann; Sherry Zhang; Tiffaney Hsia; Magdalena Cichon; Derek C Radisky; Celeste M Nelson
Journal:  Cancer Res       Date:  2018-02-26       Impact factor: 12.701

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.